Shire PLC (LON:SHP) has earned a consensus recommendation of “Buy” from the twenty brokerages that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is GBX 5,323.33 ($74.64).
SHP has been the subject of several recent research reports. Goldman Sachs Group restated a “conviction-buy” rating on shares of Shire in a report on Tuesday, October 17th. Liberum Capital decreased their price objective on Shire from GBX 4,400 ($61.69) to GBX 4,200 ($58.89) and set a “hold” rating for the company in a report on Tuesday, October 24th. Berenberg Bank decreased their price objective on Shire from GBX 6,000 ($84.13) to GBX 5,900 ($82.73) and set a “buy” rating for the company in a report on Tuesday, October 24th. Shore Capital restated a “buy” rating on shares of Shire in a report on Thursday, October 26th. Finally, Deutsche Bank restated a “buy” rating and set a GBX 5,700 ($79.92) price objective on shares of Shire in a report on Thursday, October 26th.
In other Shire news, insider Dominic Blakemore acquired 165 shares of the business’s stock in a transaction on Tuesday, December 19th. The shares were acquired at an average price of GBX 3,790 ($53.14) per share, with a total value of £6,253.50 ($8,768.23).
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.